Gradient Investments LLC Has $19.99 Million Stake in Boston Scientific Corporation $BSX

Gradient Investments LLC raised its position in shares of Boston Scientific Corporation (NYSE:BSX) by 82.0% during the 2nd quarter, Holdings Channel.com reports. The firm owned 468,335 shares of the medical equipment provider’s stock after acquiring an additional 211,067 shares during the period. Gradient Investments LLC’s holdings in Boston Scientific were worth $19,989,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of BSX. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the second quarter valued at $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific in the 4th quarter worth about $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific during the 4th quarter worth about $26,000. Clal Insurance Enterprises Holdings Ltd acquired a new stake in Boston Scientific during the 1st quarter worth about $28,000. Finally, Sfam LLC purchased a new position in Boston Scientific during the 4th quarter valued at about $29,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.1%

Shares of Boston Scientific stock opened at $49.35 on Friday. The firm has a market cap of $71.53 billion, a price-to-earnings ratio of 19.98, a P/E/G ratio of 1.08 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 1.22. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The stock has a 50-day simple moving average of $45.75 and a 200-day simple moving average of $60.73.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has initiated a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on BSX shares. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a research report on Thursday, May 28th. Jefferies Financial Group dropped their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. BTIG Research cut their target price on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $60.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David C. Habiger acquired 2,100 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 204,322 shares of company stock valued at $9,939,221. 0.34% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.